ArticleCureus2023
Ocular Complications in Patients on Highly Active Antiretroviral Therapy: A Case Report.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Fighting nature with nature: antiviral compounds that target retroviruses.Archives of microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our article aims to report the ocular adverse effects of highly active antiretroviral therapy (HAART). In case 1, a 26-year-old male patient presented with a diminution of vision. In the absence of active cytomegalovirus (CMV) retinitis and a surge in CD4 count of more than 100 cells/µL over four months, he was diagnosed as a case of immune recovery uveitis (IRU). He responded well to topical steroids and cycloplegics. In case 2, while dry eye is a common adverse effect of HAART, our 53-year-old female patient progressed to a visually distressing stage of keratoconjunctivitis sicca. She responded to lubricants and continues to be on the same. In case 3, a 14-year-old female patient's vision succumbed to Stevens-Johnson syndrome due to nevirapine in the absence of timely intervention. Though uncommon, debilitating ocular adverse effects may be seen with HAART. Further studies and reporting are required for an increased awareness among physicians and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.